ArticleGels (Basel, Switzerland)2026
Collagen-Enriched Immunomodulatory Hydrogel for Tendon Regeneration.
Article in Gels (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rotator cuff tendon injury (RCTI) is aggravated by the pro-inflammatory milieu elicited by TLR4 and TREM1 signaling. Hence, tendon tissue engineering approaches require considerations that address these inflammatory episodes to benefit active regenerative responses. The objective of this study was to engineer and evaluate the immunocompatibility of a tendon-mimetic hydrogel composed of a chitosan-polyvinyl alcohol (PVA) blend incorporated with Collagen-I and to assess LR12 delivery for addressing TREM1-driven inflammation in RCTI management. A chitosan-PVA-HEMA-Acrylic acid (CPHA) hydrogel was synthesized by blending the linear natural polysaccharide chitosan and linear synthetic polymer PVA in an aqueous phase, followed by incorporation and redox chain growth with HEMA using acrylic acid (AA). Interpenetration of Collagen-I in CPHA yielded the CPHA-C hydrogel. CPHA and CPHA-C hydrogels displayed ample surface functional moieties provided by the co-polymers, exhibited excellent porosity as revealed by SEM imaging (28.65 ± 6.85 and 41.56 ± 18.00, respectively, for CPHA and CPHA-C), and were amphiphilic, as evident by contact angle analysis (~70 for CPHA and CPHA-C). Both hydrogels displayed a progressive release profile for the TREM1-inhibitory peptide LR12 for 7 days, whereas the LR12-loaded CPHA hydrogel exhibited increased TREM1 inhibition in LPS-challenged RAW264.7 macrophages. CPHA and CPHA-C hydrogels were immunocompatible and masked the oxidative damage in RAW264.7 macrophages, as evident by decreased levels of mitochondrial superoxide and ROS. Additionally, the CPHA hydrogel displayed an increased TGFβ/TLR4 ratio (0.24), whereas the CPHA-C (-0.52) system showed a decreased ratio upon exposure to tenocytes and macrophages. Overall, the findings highlight the potential of CPHA and CPHA-C hydrogels as candidates for tendon regenerative applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.